Barclays PLC Has $116,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Barclays PLC increased its position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 281.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,288 shares of the company’s stock after buying an additional 6,855 shares during the quarter. Barclays PLC’s holdings in Gyre Therapeutics were worth $116,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new position in shares of Gyre Therapeutics during the second quarter worth approximately $218,000. Rhumbline Advisers bought a new position in shares of Gyre Therapeutics in the second quarter valued at $123,000. Renaissance Technologies LLC bought a new position in shares of Gyre Therapeutics in the second quarter valued at $166,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP bought a new stake in shares of Gyre Therapeutics during the third quarter worth about $334,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Stock Down 0.9 %

Shares of NASDAQ GYRE opened at $10.60 on Friday. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $26.37. The firm’s 50-day simple moving average is $11.21 and its 200 day simple moving average is $12.60.

Insider Transactions at Gyre Therapeutics

In related news, President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 18,054 shares of company stock valued at $207,337 over the last ninety days. 19.52% of the stock is currently owned by insiders.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.